The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic product have approval to treat three eye conditions that lead to vision loss.
Vir Biotechnology, based in San Francisco, has lately made several high-profile development and manufacturing deals with drug companies as well as contract manufacturers, amid the Covid-19 pandemic. Manufacturing is expected to start in October.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Korea's news agency Yonhap reported that the executive, surnamed Lee, allegedly decided to tamper with evidence of a plot to inflate the value of Samsung's stake in a joint venture with a U.S. company.